Characteristics of the patients with B-PLL
| Parameter . | Whole cohort (N = 34) . |
|---|---|
| Age at diagnosis, median (range), y | 72 (46.2-87.9) |
| Sex, male/female | 20/14 |
| Splenomegaly, n/N (%) | 18/31 (58) |
| Lymphadenopathy, n/N (%) | 6/31 (19) |
| Lymphocytosis, median (range), G/L | 36 (4.6-244) |
| Prolymphocytes, median (range), % | 79.5 (60-100) |
| Treated patients, n/N (%) | 29/33 (88) |
| Death, n/N (%) | 14/33 (42) |
| Follow-up, median (range), mo | 47 (0.2-141) |
| OS, median (95% CI), mo | 125.7 (52.3-132.1) |
| TTT, median (95% CI), mo | 5.8 (1.5-27.5) |
| CD38+, n/N (%) | 20/33 (61) |
| Matutes score, n/N (%) | |
| 0 | 8/33 (25) |
| 1 | 11/33 (33) |
| 2 | 9/33 (27) |
| 3 | 5/33 (15) |
| CD5+, n/N (%) | 19/34 (56) |
| CD23+, n/N (%) | 11/34 (32) |
| CK (≥3 abnormalities)*, n/N (%) | 24/33 (73) |
| HCK (≥5 abnormalities)*, n/N (%) | 15/33 (45) |
| No. of karyotypic aberrations, median (range)* | 4 (1-21) |
| Unbalanced translocations*, n/N (%) | 23/33 (70) |
| t(MYC), n/N (%) | 21/34 (62) |
| del17p (TP53), n/N (%) | 13/34 (38) |
| tri12, n/N (%) | 8/34 (24) |
| tri3, n/N (%) | 8/33 (24) |
| tri18, n/N (%) | 10/33 (30) |
| MYC gain, n/N (%) | 5/34 (15) |
| del13q, n/N (%) | 10/34 (29) |
| del8p (TNFRSF10), n/N (%) | 7/31 (23) |
| IGHV mutated, n/N (%) | 16/19 (84) |
| TP53 mutated, n/N (%) | 6/16 (38) |
| MYD88 mutated, n/N (%) | 4/16 (25) |
| BCOR mutated, n/N (%) | 4/16 (25) |
| MYC mutated, n/N (%) | 3/16 (19) |
| SF3B1 mutated, n/N (%) | 3/16 (19) |
| Parameter . | Whole cohort (N = 34) . |
|---|---|
| Age at diagnosis, median (range), y | 72 (46.2-87.9) |
| Sex, male/female | 20/14 |
| Splenomegaly, n/N (%) | 18/31 (58) |
| Lymphadenopathy, n/N (%) | 6/31 (19) |
| Lymphocytosis, median (range), G/L | 36 (4.6-244) |
| Prolymphocytes, median (range), % | 79.5 (60-100) |
| Treated patients, n/N (%) | 29/33 (88) |
| Death, n/N (%) | 14/33 (42) |
| Follow-up, median (range), mo | 47 (0.2-141) |
| OS, median (95% CI), mo | 125.7 (52.3-132.1) |
| TTT, median (95% CI), mo | 5.8 (1.5-27.5) |
| CD38+, n/N (%) | 20/33 (61) |
| Matutes score, n/N (%) | |
| 0 | 8/33 (25) |
| 1 | 11/33 (33) |
| 2 | 9/33 (27) |
| 3 | 5/33 (15) |
| CD5+, n/N (%) | 19/34 (56) |
| CD23+, n/N (%) | 11/34 (32) |
| CK (≥3 abnormalities)*, n/N (%) | 24/33 (73) |
| HCK (≥5 abnormalities)*, n/N (%) | 15/33 (45) |
| No. of karyotypic aberrations, median (range)* | 4 (1-21) |
| Unbalanced translocations*, n/N (%) | 23/33 (70) |
| t(MYC), n/N (%) | 21/34 (62) |
| del17p (TP53), n/N (%) | 13/34 (38) |
| tri12, n/N (%) | 8/34 (24) |
| tri3, n/N (%) | 8/33 (24) |
| tri18, n/N (%) | 10/33 (30) |
| MYC gain, n/N (%) | 5/34 (15) |
| del13q, n/N (%) | 10/34 (29) |
| del8p (TNFRSF10), n/N (%) | 7/31 (23) |
| IGHV mutated, n/N (%) | 16/19 (84) |
| TP53 mutated, n/N (%) | 6/16 (38) |
| MYD88 mutated, n/N (%) | 4/16 (25) |
| BCOR mutated, n/N (%) | 4/16 (25) |
| MYC mutated, n/N (%) | 3/16 (19) |
| SF3B1 mutated, n/N (%) | 3/16 (19) |
CI, confidence interval; TTT, time to first treatment.
The frequency of chromosomal abnormalities did not differ significantly when comparing patients at diagnosis vs patients during follow-up and treated patients vs untreated patients.